Biocon Shares Drop 4% Amid Heavy Trading Activity
Biocon shares slip 4% amid heavy volumes; 9.58 mn shares traded on NSE
Business Standard
Image: Business Standard
Biocon's shares fell by 4% on the National Stock Exchange (NSE), trading at ₹340.8 per share with 9.58 million shares exchanged. Chairperson Kiran Mazumdar-Shaw emphasized the company's commitment to insulin production amid a global shift towards newer diabetes therapies, aiming to become a leading insulin provider.
- 01Biocon shares declined 4% to ₹340.8 per share amid heavy trading.
- 02A total of 9.58 million shares were traded on the NSE.
- 03Chairperson Kiran Mazumdar-Shaw highlighted Biocon's focus on insulin production.
- 04The company aims to capitalize on a growing global diabetes market.
- 05Biocon plans to expand its presence in 80 markets with insulin approvals.
Advertisement
In-Article Ad
Biocon's shares experienced a 4% decline, reaching an intra-day low of ₹340.7 per share on the National Stock Exchange (NSE) with 9.58 million shares traded. This drop occurred while the NSE Nifty50 index fell by 0.13%. Chairperson Kiran Mazumdar-Shaw stated that Biocon is positioning itself as a leader in the insulin market, especially as larger competitors shift focus to GLP-1 therapies. She noted that while GLP-1 drugs are promising, they have limitations for Type-1 and late-stage Type-2 diabetics, ensuring the continued necessity of insulin. Biocon aims to maximize value through strategic capital allocation, focusing on insulin production where margins are favorable compared to GLP-1 drugs. New MD and CEO Shreehas Tambe underscored the company's commitment to making life-saving drugs affordable and targeting growth in diabetes care, projecting a 45% increase in global diabetes cases over the next decade, reaching 850 million patients.
Advertisement
In-Article Ad
The decline in Biocon's share price may affect investor confidence and could impact funding for future projects, potentially influencing the availability of affordable diabetes treatments.
Advertisement
In-Article Ad
Reader Poll
Do you believe Biocon can successfully lead the insulin market?
Connecting to poll...
More about Biocon
Read the original article
Visit the source for the complete story.



